Developer docs
API playgroundTry for free, no card

Search company profiles

Made Scientific

Full company profile

uuid0002oxj

Namestring
Made Scientific
Legal namestring
Made Scientific, Inc.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Made Scientific is a cell therapy contract development and manufacturing organization (CDMO) founded in 2019 and headquartered in Princeton, New Jersey. The company provides end-to-end GMP manufacturing services for autologous and allogeneic cell therapies, spanning T cells, NK cells, HSCs, MSCs, iPSCs, TILs, and exosomes, and serves biotech companies, pharmaceutical firms, and academic institutions from pre-clinical development through commercial phases. Its service portfolio includes process and analytical development, GMP cell banking and drug product manufacture, aseptic fill and finish, QC lot release and stability studies, and regulatory consulting for IND and BLA submissions.

The company's technical platform is anchored by a 60,000 ft² Princeton facility equipped with 5 ISO 7/Grade B cleanrooms, BSL-2 compliance, and infrastructure meeting US FDA (21 CFR 1271, 21 CFR 210/211) and EU Annex 1 standards. Recent capability additions include the MadeFast™ single-step CAR-T manufacturing platform with RapidCell™, an iPSC manufacturing platform integrated with Pluristyx's GMP iPSC lines and derivative cell types (iNK, iMSC), and an AI-driven robotic automation platform developed through an exclusive partnership with Streamline Bio. A 12,000 ft² expansion adding 9,000 ft² of new GMP cleanroom space is underway, with full capacity projected to deliver approximately 5,000 additional manufacturing batches per year.

Made Scientific operates a B2B, consultative sales model with project-based contracts, dedicated capacity agreements, and per-batch manufacturing fees; pricing is quote-based and negotiated per project rather than tier-based or subscription. The company is privately held and backed by GC Corporation of South Korea as a long-term strategic shareholder, with two GC executives (Jin Pyun and Soyoung Park) holding board seats. GTM combines direct enterprise sales to cell therapy developers, technical content marketing through the website's insights section, LinkedIn presence, and participation in advanced therapy conferences such as ISSCR 2026 and Meeting on the Mesa. The Made Scientific Foundry™ workforce development program, with Core, Boost, and Scholar tracks, supports training on actual CDMO equipment and includes an academic collaboration with NJIT.

Short descriptiontext

Made Scientific is a Princeton, NJ-based cell therapy CDMO founded in 2019, providing end-to-end GMP manufacturing, process development, and analytical services for autologous and allogeneic therapies. Backed by South Korea's GC Corporation, it serves biotech, pharma, and academic clients from preclinical through commercial phases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, contract development services, GMP drug product, aseptic fill finish, process analytical development
Industry3 codes
SECONDARYHLAGABAD
Cell Therapy CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cell Therapy Contract Development & Manufacturing (CDMO)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Development and Manufacturing Services
TypeManaged Services
Description

Full-service CDMO providing end-to-end cell therapy manufacturing services from pre-clinical through commercial phases. Revenue generated through project-based contracts, dedicated capacity agreements, and per-batch manufacturing fees. Services include process development, GMP manufacturing, quality control, regulatory consulting, and fill-finish services.

madescientific.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Made Scientific Foundry
Description

Workforce development and training program offering in-person lab immersion, live-virtual courses, GMP-aligned training on actual CDMO equipment and workflows, academic collaborations and custom program development.

madescientific.com
Core offering1 text field

Made Scientific is a cell therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for autologous and allogeneic cell therapies including T cells, NK cells, HSCs, MSCs, iPSCs, TILs, and exosomes. Its offerings span process and analytical development, GMP drug product manufacture, aseptic fill and finish, QC lot release and stability studies, and regulatory consulting, supported by the MadeFast™ single-step CAR-T platform, an AI-driven robotic manufacturing partnership with Streamline Bio, and an integrated iPSC platform with Pluristyx.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Enables developers to begin GMP manufacturing on day one with pre-qualified starting materials meeting 21 CFR 1271 and 21 CFR 210/211 compliance
+2 more records
Product overview1 text field

Made Scientific is a cell therapy Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of manufacturing and development services. The core offering includes GMP cell therapy manufacturing, process & analytical development, aseptic fill & finish, quality control testing, and regulatory consulting. The portfolio is enhanced by the AI-driven Robotic Manufacturing Platform (via Streamline Bio partnership) for autonomous workflows, the iPSC Manufacturing Platform (via Pluristyx partnership) for GMP-ready induced pluripotent stem cell lines and derivatives, and the MadeFast™ CAR-T Manufacturing Platform with RapidCell™ for single-step rapid cell therapy production. The Made Scientific Foundry workforce development program (Core, Boost, Scholar tracks) supports training across these platforms. The company operates from a 60,000 ft² facility in Princeton, NJ with 5 ISO 7/Grade B cleanrooms, currently expanding by 12,000 ft² with 9,000 ft² of new GMP cleanroom space incorporating AI-driven robotic automation.

Product and service9 records
1GMP Cell Therapy Manufacturing
CategoryCell Therapy CDMO Services
Description

End-to-end GMP manufacturing services for cell therapies spanning clinical-to-commercial stages using Princeton facility infrastructure including ISO 7 / Grade B cleanrooms and BSL-2 compliance, serving biotech and pharmaceutical developers.

2Process & Analytical Development
CategoryCell Therapy CDMO Services
Description

Process development and analytical method development services that identify cell therapy product quality attributes and critical process parameters early, supporting tech transfer into GMP manufacturing for cell therapy developers.

3GMP Aseptic Fill & Finish
CategoryCell Therapy CDMO Services
Description

Aseptic fill and finish services for cell therapy drug products ensuring GMP-compliant final drug product manufacturing under FDA and EMA standards.

4Quality Control Testing & Stability Studies
CategoryCell Therapy CDMO Services
Description

QC lot release and stability testing services for cell therapy products operated via in-house laboratory capabilities at the Princeton facility.

5Regulatory Consulting
CategoryCell Therapy CDMO Services
Description

Regulatory consulting services supporting IND and BLA submissions for cell therapy developers, covering FDA and EMA regulatory pathways including Annex 1 compliance.

6Workforce Development & Training (Made Scientific Foundry)
CategoryTraining and Workforce Development
Description

GMP-aligned workforce training program offering in-person lab immersion, live-virtual courses, and academic collaborations across three tracks — Core (in-person), Boost (virtual), and Scholar (academic partnerships) — for cell therapy professionals.

7AI-Driven Robotic Manufacturing Platform
CategoryCell Therapy Manufacturing Platforms
Description

AI-driven robotic automation platform for cell therapy manufacturing enabling autonomous workflows in GMP environments, targeting rapid CAR-T production through end-to-end automation of critical process steps to reduce cycle times and cost of goods.

8iPSC Manufacturing Platform
CategoryCell Therapy Manufacturing Platforms
Description

Integrated iPSC development and manufacturing platform leveraging Pluristyx's GMP-ready iPSC lines and derivative cell types including iNK and iMSC, providing cell therapy developers a single-source path from cell line to commercial supply compliant with FDA and EMA standards.

9MadeFast™ CAR-T Manufacturing Platform
CategoryCell Therapy Manufacturing Platforms
Description

MadeFast™ single-step CAR-T manufacturing platform utilizing RapidCell™ technology for accelerated production of engineered cell therapies, enabling rapid autonomous cell therapy manufacturing.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

Strategic partnership integrating Pluristyx's GMP iPSC platform into Made Scientific's end-to-end CDMO services. Pluristyx serves as Made Scientific's iPSC supply and development partner, providing GMP-ready iPSC lines and derivative cell types (iNK, iMSC) for FDA, EMA, and global regulatory compliance. The partnership aims to compress IND timelines and reduce program costs by enabling developers to begin GMP manufacturing day one.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Manufacturing partnership to advance NovaDerm, an autologous cultured skin substitute for severe burns and chronic wounds, toward FDA Orphan product approval. Made Scientific provides end-to-end manufacturing services at its Princeton GMP facility including technology transfer, GMP clinical production, and regulatory support.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Technology transfer and manufacturing partnership for HG-CT-1 CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia. Successfully completed tech transfer with FDA comparability data package confirming product equivalence between internally and externally manufactured batches.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

Partnership to co-develop graduate-level bioprocessing elective courses within NJIT's Master of Science program in Chemical and Materials Engineering. Leverages Made Scientific Foundry scholar program to deliver industry-aligned curriculum launching Spring 2027. Aims to prepare next generation of cell and gene therapy professionals.

5Streamline Bio
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-02-10
Description

Exclusive Early Adopter and Design Partner Program for AI-driven robotic manufacturing platform. Made Scientific serves as Streamline Bio's exclusive CDMO partner for the technology. Collaboration focuses on co-developing and validating autonomous CAR-T manufacturing through end-to-end automation of critical process steps, aiming to optimize cycle times and reduce cost of goods.

morningstar.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

Three-way strategic partnership with Cytora Therapeutics and Zeo ScientifiX for manufacturing and commercialization of Cytora's allogeneic human oral mucosal stem cell therapy. Made Scientific serves as exclusive U.S. GMP manufacturing partner from its Princeton facility while Zeo handles U.S. commercialization. Initial focus on diabetic foot ulcers with plans for FDA Phase 2b clinical trials.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-07
Description

Exclusive U.S. commercialization partner in three-way partnership with Cytora Therapeutics and Made Scientific for stem cell therapy distribution. Handles market access and commercialization, initially leveraging Florida's Senate Bill 1768 stem cell access law.

8Cellergy Therapeutics
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Partnership to advance Cellergy's mitochondrial therapy candidate CLG-001 toward first-in-human clinical studies. Made Scientific provides GMP manufacturing capabilities for trials under Israel's Ministry of Health compassionate-use framework and U.S. FDA Phase I study.

synbiobeta.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Made Scientific

Cell Therapy Contract Development & Manufacturing (CDMO)madescientific.com

Made Scientific is a Princeton, NJ-based cell therapy CDMO founded in 2019, providing end-to-end GMP manufacturing, process development, and analytical services for autologous and allogeneic therapies. Backed by South Korea's GC Corporation, it serves biotech, pharma, and academic clients from preclinical through commercial phases.

What Made Scientific does

Made Scientific is a cell therapy contract development and manufacturing organization (CDMO) founded in 2019 and headquartered in Princeton, New Jersey. The company provides end-to-end GMP manufacturing services for autologous and allogeneic cell therapies, spanning T cells, NK cells, HSCs, MSCs, iPSCs, TILs, and exosomes, and serves biotech companies, pharmaceutical firms, and academic institutions from pre-clinical development through commercial phases. Its service portfolio includes process and analytical development, GMP cell banking and drug product manufacture, aseptic fill and finish, QC lot release and stability studies, and regulatory consulting for IND and BLA submissions.

The company's technical platform is anchored by a 60,000 ft² Princeton facility equipped with 5 ISO 7/Grade B cleanrooms, BSL-2 compliance, and infrastructure meeting US FDA (21 CFR 1271, 21 CFR 210/211) and EU Annex 1 standards. Recent capability additions include the MadeFast™ single-step CAR-T manufacturing platform with RapidCell™, an iPSC manufacturing platform integrated with Pluristyx's GMP iPSC lines and derivative cell types (iNK, iMSC), and an AI-driven robotic automation platform developed through an exclusive partnership with Streamline Bio. A 12,000 ft² expansion adding 9,000 ft² of new GMP cleanroom space is underway, with full capacity projected to deliver approximately 5,000 additional manufacturing batches per year.

Made Scientific operates a B2B, consultative sales model with project-based contracts, dedicated capacity agreements, and per-batch manufacturing fees; pricing is quote-based and negotiated per project rather than tier-based or subscription. The company is privately held and backed by GC Corporation of South Korea as a long-term strategic shareholder, with two GC executives (Jin Pyun and Soyoung Park) holding board seats. GTM combines direct enterprise sales to cell therapy developers, technical content marketing through the website's insights section, LinkedIn presence, and participation in advanced therapy conferences such as ISSCR 2026 and Meeting on the Mesa. The Made Scientific Foundry™ workforce development program, with Core, Boost, and Scholar tracks, supports training on actual CDMO equipment and includes an academic collaboration with NJIT.

Made Scientific firmographics

Firmographics
Name
Made Scientific
Legal name
Made Scientific, Inc.
Website
https://madescientific.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Made Scientific is a Princeton, NJ-based cell therapy CDMO founded in 2019, providing end-to-end GMP manufacturing, process development, and analytical services for autologous and allogeneic therapies. Backed by South Korea's GC Corporation, it serves biotech, pharma, and academic clients from preclinical through commercial phases.
Ownership category
akta.pro rank

Where Made Scientific is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Made Scientific business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Development and Manufacturing Services: Full-service CDMO providing end-to-end cell therapy manufacturing services from pre-clinical through commercial phases. Revenue generated through project-based contracts, dedicated capacity agreements, and per-batch manufacturing fees. Services include process development, GMP manufacturing, quality control, regulatory consulting, and fill-finish services.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Made Scientific product offering

Product offering

Core offering

Made Scientific is a cell therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for autologous and allogeneic cell therapies including T cells, NK cells, HSCs, MSCs, iPSCs, TILs, and exosomes. Its offerings span process and analytical development, GMP drug product manufacture, aseptic fill and finish, QC lot release and stability studies, and regulatory consulting, supported by the MadeFast™ single-step CAR-T platform, an AI-driven robotic manufacturing partnership with Streamline Bio, and an integrated iPSC platform with Pluristyx.

Product overview

Made Scientific is a cell therapy Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of manufacturing and development services. The core offering includes GMP cell therapy manufacturing, process & analytical development, aseptic fill & finish, quality control testing, and regulatory consulting. The portfolio is enhanced by the AI-driven Robotic Manufacturing Platform (via Streamline Bio partnership) for autonomous workflows, the iPSC Manufacturing Platform (via Pluristyx partnership) for GMP-ready induced pluripotent stem cell lines and derivatives, and the MadeFast™ CAR-T Manufacturing Platform with RapidCell™ for single-step rapid cell therapy production. The Made Scientific Foundry workforce development program (Core, Boost, Scholar tracks) supports training across these platforms. The company operates from a 60,000 ft² facility in Princeton, NJ with 5 ISO 7/Grade B cleanrooms, currently expanding by 12,000 ft² with 9,000 ft² of new GMP cleanroom space incorporating AI-driven robotic automation.

Differentiator

Problem solved

Functional benefit

Brands

  • Made Scientific Foundry: Workforce development and training program offering in-person lab immersion, live-virtual courses, GMP-aligned training on actual CDMO equipment and workflows, academic collaborations and custom program development.

Products and services

  • GMP Cell Therapy Manufacturing End-to-end GMP manufacturing services for cell therapies spanning clinical-to-commercial stages using Princeton facility infrastructure including ISO 7 / Grade B cleanrooms and BSL-2 compliance, serving biotech and pharmaceutical developers.
  • Process & Analytical Development Process development and analytical method development services that identify cell therapy product quality attributes and critical process parameters early, supporting tech transfer into GMP manufacturing for cell therapy developers.
  • GMP Aseptic Fill & Finish Aseptic fill and finish services for cell therapy drug products ensuring GMP-compliant final drug product manufacturing under FDA and EMA standards.
  • Quality Control Testing & Stability Studies QC lot release and stability testing services for cell therapy products operated via in-house laboratory capabilities at the Princeton facility.
  • Regulatory Consulting Regulatory consulting services supporting IND and BLA submissions for cell therapy developers, covering FDA and EMA regulatory pathways including Annex 1 compliance.
  • Workforce Development & Training (Made Scientific Foundry) GMP-aligned workforce training program offering in-person lab immersion, live-virtual courses, and academic collaborations across three tracks — Core (in-person), Boost (virtual), and Scholar (academic partnerships) — for cell therapy professionals.
  • AI-Driven Robotic Manufacturing Platform AI-driven robotic automation platform for cell therapy manufacturing enabling autonomous workflows in GMP environments, targeting rapid CAR-T production through end-to-end automation of critical process steps to reduce cycle times and cost of goods.
  • iPSC Manufacturing Platform Integrated iPSC development and manufacturing platform leveraging Pluristyx's GMP-ready iPSC lines and derivative cell types including iNK and iMSC, providing cell therapy developers a single-source path from cell line to commercial supply compliant with FDA and EMA standards.
  • MadeFast™ CAR-T Manufacturing Platform MadeFast™ single-step CAR-T manufacturing platform utilizing RapidCell™ technology for accelerated production of engineered cell therapies, enabling rapid autonomous cell therapy manufacturing.

Quantifiable outcome

  • Enables developers to begin GMP manufacturing on day one with pre-qualified starting materials meeting 21 CFR 1271 and 21 CFR 210/211 compliance
  • +2 more outcomes

Companies that use Made Scientific

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Made Scientific technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Made Scientific partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • PluristyxcoreStrategic or Co-development Partner · 4 June 2026Strategic partnership integrating Pluristyx's GMP iPSC platform into Made Scientific's end-to-end CDMO services. Pluristyx serves as Made Scientific's iPSC supply and development partner, providing GMP-ready iPSC lines and derivative cell types (iNK, iMSC) for FDA, EMA, and global regulatory compliance. The partnership aims to compress IND timelines and reduce program costs by enabling developers to begin GMP manufacturing day one.
  • RegenicinminorStrategic or Co-development Partner · 22 April 2026Manufacturing partnership to advance NovaDerm, an autologous cultured skin substitute for severe burns and chronic wounds, toward FDA Orphan product approval. Made Scientific provides end-to-end manufacturing services at its Princeton GMP facility including technology transfer, GMP clinical production, and regulatory support.
  • Hemogenyx PharmaceuticalsminorStrategic or Co-development Partner · 31 March 2026Technology transfer and manufacturing partnership for HG-CT-1 CAR-T cell therapy targeting relapsed/refractory acute myeloid leukemia. Successfully completed tech transfer with FDA comparability data package confirming product equivalence between internally and externally manufactured batches.
  • New Jersey Institute of Technology (NJIT)minorStrategic or Co-development Partner · 26 March 2026Partnership to co-develop graduate-level bioprocessing elective courses within NJIT's Master of Science program in Chemical and Materials Engineering. Leverages Made Scientific Foundry scholar program to deliver industry-aligned curriculum launching Spring 2027. Aims to prepare next generation of cell and gene therapy professionals.
  • Streamline BiocoreTechnology or Integration · 10 February 2026Exclusive Early Adopter and Design Partner Program for AI-driven robotic manufacturing platform. Made Scientific serves as Streamline Bio's exclusive CDMO partner for the technology. Collaboration focuses on co-developing and validating autonomous CAR-T manufacturing through end-to-end automation of critical process steps, aiming to optimize cycle times and reduce cost of goods.
  • Cytora TherapeuticscoreStrategic or Co-development Partner · 7 January 2026Three-way strategic partnership with Cytora Therapeutics and Zeo ScientifiX for manufacturing and commercialization of Cytora's allogeneic human oral mucosal stem cell therapy. Made Scientific serves as exclusive U.S. GMP manufacturing partner from its Princeton facility while Zeo handles U.S. commercialization. Initial focus on diabetic foot ulcers with plans for FDA Phase 2b clinical trials.
  • Zeo ScientifiXcoreChannel Partner/ Reseller/ Distributor · 7 January 2026Exclusive U.S. commercialization partner in three-way partnership with Cytora Therapeutics and Made Scientific for stem cell therapy distribution. Handles market access and commercialization, initially leveraging Florida's Senate Bill 1768 stem cell access law.
  • Cellergy TherapeuticsminorStrategic or Co-development Partner · 18 December 2025Partnership to advance Cellergy's mitochondrial therapy candidate CLG-001 toward first-in-human clinical studies. Made Scientific provides GMP manufacturing capabilities for trials under Israel's Ministry of Health compassionate-use framework and U.S. FDA Phase I study.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Made Scientific competitors and assessment

Company assessment

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

Made Scientific social profiles

Digital presence

Made Scientific compliance and trust

Trust signal

Compliance6 records

Made Scientific financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Made Scientific leadership team

Management profile

Number of profiles

Profiles8 records

Made Scientific funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Made Scientific M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Made Scientific

What does Made Scientific do?

Made Scientific is a cell therapy Contract Development and Manufacturing Organization (CDMO) providing end-to-end GMP manufacturing services for autologous and allogeneic cell therapies including T cells, NK cells, HSCs, MSCs, iPSCs, TILs, and exosomes. Its offerings span process and analytical development, GMP drug product manufacture, aseptic fill and finish, QC lot release and stability studies, and regulatory consulting, supported by the MadeFast™ single-step CAR-T platform, an AI-driven robotic manufacturing partnership with Streamline Bio, and an integrated iPSC platform with Pluristyx.

Is Made Scientific a public or private company?

Made Scientific is a private company. It is classified as corporate owned and is currently operating.

When was Made Scientific founded?

Made Scientific was founded in 2019. It employs 101 to 250 people.

Where is Made Scientific based?

Made Scientific is headquartered in Princeton, United States, in the North America region.

How does Made Scientific make money?

One revenue line is on record: contract Development and Manufacturing Services.

Does Made Scientific have an API?

No public API is recorded for Made Scientific.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMade Scientific Announces Long-Term Commercial Manufacturing Partnership with Orca Bio for TREGZI™Made Scientific and Orca Bio announced a long-term commercial manufacturing partnership for TREGZI, with Made Scientific providing East Coast capacity in Princeton, New Jersey. The Princeton site complements Orca Bio's Sacramento facility, enabling a bicoastal network and European donor sourcing. Made Scientific plans to expand its Princeton campus by 45,000 sq. ft. to support growth.FinanzNachrichten.de200 Prozent Ausbeute, 1 geplanter GMP-Partner: Warum NurExone und Made Scientific die Exosomenproduktion skalieren wollenNurExone Biologic reported consistent protein profiles across four independent exosome batches and doubled relative yield using parallel bioreactors without extending production time. The company plans a GMP manufacturing partnership with Made Scientific, with first GMP batches targeted for the first half of 2027.PR NewswireMade Scientific and CARR Biosystems Establish Partnership to Advance Scalable MSC and Allogeneic Cell Therapy ManufacturingMade Scientific and CARR Biosystems announced a partnership to integrate CARR's UniFuge single-use centrifugation systems into Made Scientific's Princeton and East Norriton facilities. The systems will support cell harvest, wash, and concentration for 3D bioreactor platforms, with Made Scientific serving as a preferred CDMO for CARR customers. Joint development studies using the benchtop UFMini system are planned.FinanzNachrichten.deBreaking News: Der Schlüssel zum kommerziellen Tor?!NurExone Biologic Inc. doubled its exosome production by running two bioreactors in parallel, maintaining quality and process consistency. The company also signed a MOU with Made Scientific for US GMP manufacturing and commercial supply. The move supports its modular manufacturing strategy and potential commercial sales of exosomes.Pharmaceutical TechnologyMade Scientific acquires cell therapy facility in Pennsylvania, USMade Scientific acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania from National Resilience, adding an operational site to its US East Coast network. The facility can onboard programmes immediately and is intended to support clinical and commercial supply from 2027. It includes eight Grade B/C cleanrooms and 30,000ft² of expansion space.YahooCell Therapy Manufacturer Buys 85K SF Facility To Expand In Philly SuburbsMade Scientific Inc. acquired an 85,000-square-foot manufacturing facility in East Norriton, Pennsylvania, from Resilience, which sold it as a non-core asset. The buyer, a cell therapy manufacturer, said the acquisition will help bring products to market faster. The deal was not disclosed, but the facility is at 2900 Potshop Lane, about 20 miles west of Philadelphia.BisnowCell Therapy Manufacturer Buys 85K SF Facility To Expand In Philly SuburbsMade Scientific Inc. acquired an 85K SF manufacturing facility in East Norriton, Pennsylvania, from Resilience, which sold it as a non-core asset. The buyer, a cell therapy manufacturer, said the acquisition will help bring products to market faster. The deal follows expansions by Johnson & Johnson, Eli Lilly, and GSK in the region.FinanzNachrichten.deBreaking News: NurExone läutet die nächste Runde ein!NurExone Biologic Inc. announced it will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference, including one-on-one investor meetings, to support planned clinical development of its exosome-based therapy ExoPTEN. The company cited preclinical results in which 75% of treated spinal cord injury rats recovered functionally and 100% regained mobility in a high-dose group. It also reported an MOU with Made Scientific for US GMP manufacturing and commercial supply.FinanzNachrichten.deKeine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiertNurExone Biologic is developing ExoPTEN, an exosome-based therapy for acute spinal cord injuries, with no FDA-approved exosome therapies yet. The company has preclinical data showing improved myelin in rats and signed a GMP manufacturing MOU with Made Scientific, targeting first GMP batches in H1 2027.FinanzNachrichten.deNurExone Biologic: Der CEO legt die Karten auf den Tisch!A promotional press release from bullVestor, published on 25 August 2026, outlines NurExone Biologic's preclinical progress with its exosome-based candidate ExoPTEN for spinal cord injury and optic nerve damage. It cites 75% functional recovery and 100% gait recovery in a high-dose animal model, plus an EMA orphan drug designation and a completed US FDA pre-IND meeting. The company also announced a binding MOU with Made Scientific for US GMP manufacturing.